Literature DB >> 21320371

The application of an enzyme-linked immunosorbent assay or an immunofluorescent assay test leads to different estimates of seroprevalence of Coxiella burnetii in the population.

G J Blaauw1, D W Notermans, B Schimmer, J Meekelenkamp, J H J Reimerink, P Teunis, P M Schneeberger.   

Abstract

The diagnosis and epidemiological studies of Q fever depend on serology. Among the main methods employed are the enzyme-linked immunosorbent assay (ELISA) and the immunofluorescent assay test (IFAT). We show that two commercial assays representing the two methods with two different cut-off titres can lead to significant differences in diagnostic and seroprevalence estimates. This in turn emphasizes the need for a standardized gold method to compare the various assays; whether this standard is 'in-house' or commercially obtained.

Entities:  

Mesh:

Year:  2011        PMID: 21320371     DOI: 10.1017/S0950268811000021

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

1.  Evaluation of commonly used serological tests for detection of Coxiella burnetii antibodies in well-defined acute and follow-up sera.

Authors:  M C A Wegdam-Blans; C C H Wielders; J Meekelenkamp; J M Korbeeck; T Herremans; H T Tjhie; H A Bijlmer; M P G Koopmans; P M Schneeberger
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

2.  Long-Term immune responses to Coxiella burnetii after vaccination.

Authors:  Gilbert J Kersh; Kelly A Fitzpatrick; Joshua S Self; Brad J Biggerstaff; Robert F Massung
Journal:  Clin Vaccine Immunol       Date:  2012-11-28

3.  Epidemiology of brucellosis and q Fever in linked human and animal populations in northern togo.

Authors:  Anna S Dean; Bassirou Bonfoh; Abalo E Kulo; G Aboudou Boukaya; Moussa Amidou; Jan Hattendorf; Paola Pilo; Esther Schelling
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

4.  Waning population immunity prior to a large Q fever epidemic in the south of The Netherlands.

Authors:  D A H Brandwagt; T Herremans; P M Schneeberger; V H Hackert; C J P A Hoebe; J Paget; W VAN DER Hoek
Journal:  Epidemiol Infect       Date:  2016-04-14       Impact factor: 4.434

5.  Risk factors of Coxiella burnetii (Q fever) seropositivity in veterinary medicine students.

Authors:  Myrna M T de Rooij; Barbara Schimmer; Bart Versteeg; Peter Schneeberger; Boyd R Berends; Dick Heederik; Wim van der Hoek; Inge M Wouters
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

6.  Absence of convincing evidence of Coxiella burnetii infection in Chile: a cross-sectional serosurvey among healthy adults in four different regions.

Authors:  Thomas Weitzel; Javier López; Gerardo Acosta-Jamett; Sophie Edouard; Philippe Parola; Katia Abarca
Journal:  BMC Infect Dis       Date:  2016-10-06       Impact factor: 3.090

7.  The Sero-epidemiology of Coxiella burnetii in Humans and Cattle, Western Kenya: Evidence from a Cross-Sectional Study.

Authors:  Nicola A Wardrop; Lian F Thomas; Elizabeth A J Cook; William A de Glanville; Peter M Atkinson; Claire N Wamae; Eric M Fèvre
Journal:  PLoS Negl Trop Dis       Date:  2016-10-07

8.  Evidence of exposure to C. burnetii among slaughterhouse workers in western Kenya.

Authors:  Elizabeth Anne Jessie Cook; William Anson de Glanville; Lian Francesca Thomas; Alice Kiyong'a; Velma Kivali; Samuel Kariuki; Barend Mark de Clare Bronsvoort; Eric Maurice Fèvre
Journal:  One Health       Date:  2021-08-10

9.  Remarkable spatial variation in the seroprevalence of Coxiella burnetii after a large Q fever epidemic.

Authors:  Roan Pijnacker; Johan Reimerink; Lidwien A M Smit; Arianne B van Gageldonk-Lafeber; Jan-Paul Zock; Floor Borlée; Joris Yzermans; Dick J J Heederik; Catharina B M Maassen; Wim van der Hoek
Journal:  BMC Infect Dis       Date:  2017-11-21       Impact factor: 3.090

10.  Who is at risk of occupational Q fever: new insights from a multi-profession cross-sectional study.

Authors:  Tanja Groten; Karola Kuenzer; Udo Moog; Beate Hermann; Katrin Maier; Katharina Boden
Journal:  BMJ Open       Date:  2020-02-09       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.